Introduction
============

The clinical utility of screening unselected individuals for pathogenic *BRCA1/2* variants has not been established. Proponents point to (i) the well-established potential for reducing morbidity and mortality in individuals found to have a pathogenic *BRCA1/2* variant^[@bib1]^ and (ii) the significant proportion of the population with a cancer family history that would not prompt clinical attention.^[@bib2]^ Others caution that implementing population *BRCA1/2* screening is premature without evidence of clinical utility among unselected individuals.^[@bib3]^ *BRCA1/2*-associated morbidity and mortality data^[@bib4]^ are derived from individuals identified because of a personal or family history that raised suspicion of a *BRCA1/2* mutation (i.e., indication-based testing). If these benefits do not emerge from genomic screening of unselected individuals, the associated medical, psychosocial, and financial costs of surveillance and prophylactic surgery might not be justified.^[@bib3]^

Determining the clinical utility of a *BRCA1/2* screening program in unselected individuals requires longitudinal data on (i) prevalence and penetrance of pathogenic *BRCA1/2* variants in diverse, unselected populations; (ii) impact of risk management on cancer morbidity and mortality; (iii) adherence to recommended risk management in the absence of compelling family cancer history; (iv) costs associated with risk management procedures; and (v) psychological outcomes of receiving a pathogenic *BRCA* variant via the screening program.^[@bib3]^ Here we report two early measures of the impact of a *BRCA1/2* screening program among individuals previously unaware that they were carrying a pathogenic variant--risk-management initiation and cancer diagnoses prompted by results disclosure.

This assessment was performed through the Geisinger Health System (GHS) MyCode Community Health Initiative (hereafter "MyCode"), a research project in which participants' whole exome sequences are reviewed for pathogenic and likely pathogenic variants in 76 genes (including *BRCA1/2* and 54 genes originally proposed by the American College of Medical Genetics and Genomics^[@bib5]^) associated with 27 medically actionable conditions. Clinically confirmed variants are disclosed to patient--participants and their clinicians, who are supported in integrating results into care.

Materials and methods
=====================

MyCode enrollment process and targeted screening for genomic findings
---------------------------------------------------------------------

GHS established MyCode in 2007 as a discovery research initiative enabled by a biobank. Recruitment occurs in primary-care and specialty clinics throughout GHS without regard to underlying disease or cancer risk, and without specific interest in genomic testing. In 2014 GHS established a research collaboration with Regeneron Genetics Center (RGC) that includes conducting whole-exome sequencing in MyCode participants and linking sequence data to participants' electronic health record (EHR) data. After significant engagement with patient--partners, ethicists, and clinicians, GHS developed an institutional review board--approved protocol (GenomeFIRST) to assess MyCode participants' exomes for medically actionable findings in 76 genes (including *BRCA1/2*), confirm results in a Clinical Laboratory Improvement Amendments--certified clinical diagnostic laboratory (Laboratory for Molecular Medicine, LMM), return clinically confirmed results to patient--participants and clinicians, initiate guidelines-based risk assessment and management, and facilitate cascade testing for at-risk family members.^[@bib6]^

Whole-exome sequencing and variant classification
-------------------------------------------------

Whole-exome sequencing is performed at RGC as described elsewhere.^[@bib7]^ Independent teams at GHS, RGC, and the LMM perform bioinformatics reviews of *BRCA1/2* variant call files and agree to consensus classification as pathogenic or likely pathogenic according to American College of Medical Genetics and Genomics criteria.^[@bib8]^ An independent DNA sample is sent to the LMM for Sanger confirmation of the variants. After this confirmation the LMM sends a clinical laboratory report to the Geisinger Clinical Genomics team.

Clinical program for returning genomic results
----------------------------------------------

In the cases described in this brief report, the Geisinger Clinical Genomics team (genetic counselors, medical geneticists, a nurse practitioner, and administrative staff) received the clinical laboratory report of the pathogenic variant and initiated a disclosure and follow-up protocol. After Clinical Genomics notified the primary-care physician (PCP) and patient--participant, Geisinger's multidisciplinary Inherited Risk Breast Clinic (genetic counselor, breast surgeon, physician assistant, breast oncologist, and clinical psychologist), Clinical Genomics, and PCPs coordinated medical evaluation^[@bib9]^ and cancer risk management. Risk management recommendations were based on National Comprehensive Cancer Network guidelines (which include serial sectioning of fallopian tubes following risk-reducing salpingo-oophorectomy, and prostate cancer surveillance for men with a pathogenic *BRCA2* variant).^[@bib10]^

Tracking clinical outcomes
--------------------------

The Clinical Genomics team defined outcomes relevant to recommended risk management and cancer diagnoses and tracked them via EHR review. These standardized outcomes (including dates and results of *BRCA1/2*-associated surveillance and prophylactic surgery and diagnoses of *BRCA1/2*-associated cancers) were aggregated in a database maintained for all participants with a disclosed result. We chose to assess outcomes at 12 months after disclosure to allow sufficient time for patient--participants to have undergone evaluation and to initiate risk management. For females, mammogram, breast magnetic resonance imaging (MRI), risk-reducing mastectomy, risk-reducing salpingo-oophorectomy, CA125 testing, and transvaginal ultrasound were considered to be *BRCA1/2*-associated, per National Comprehensive Cancer Network guidelines.^[@bib10]^ For males, clinical breast exam and prostate-specific antigen (PSA) testing were considered to be *BRCA1/2-*associated. We considered melanoma and breast, ovarian, prostate, and pancreatic cancers to be *BRCA1/2*-associated.

Results
=======

As of 1 April 2017, 55 MyCode participants and their PCPs had been notified of a clinically confirmed pathogenic/likely pathogenic *BRCA1/2* variant and followed for at least 12 months. Seven of these were already aware of their *BRCA1/2* variant via clinical testing. An additional 11 had a personal history of *BRCA1/2*-associated cancer. The remaining 37 patient--participants included 17 females (46%) and had a median age of 60 years (mean 56.1 years, range 26--87 years).

Of the 33 patient--participants old enough to perform *BRCA1/2*-associated risk management, 26 (79%, 15 females, 11 males) had performed at least one such behavior. Three of these patient-participants were diagnosed via these procedures with an early-stage, *BRCA1/2*-associated cancer, a subclinical phenotype revealed through evaluation.^[@bib9]^

The first patient--participant was a 56-year-old woman with a pathogenic *BRCA1* variant (ClinVar variation ID 125513). Her medical history was positive for Crohn's disease and she had had a basal cell carcinoma removed in her 40s, but the history was otherwise negative for cancer. EHR-documented family history ([Figure 1a](#fig1){ref-type="fig"}) did not meet guidelines for referral to genetic counseling.^[@bib10]^ Her most recent screening mammogram, made at age 52, was normal. Following disclosure she had a normal mammogram, breast MRI, CA125 testing, pelvic ultrasound, and a risk-reducing salpingo-oophorectomy ([Figure 2](#fig2){ref-type="fig"}). Final pathology on a 1.4 cm mass first found intraoperatively during the risk-reducing salpingo-oophorectomy revealed a high-grade, serous carcinoma with stromal invasion and a focal serous tubal intraepithelial carcinoma in the right fallopian tube ([Supplementary Figure 1a and b](#sup1){ref-type="supplementary-material"} online). Peritoneal washes demonstrated malignant cells, indicating stage 1C, which has a 5-year survival of 85%.^[@bib11]^

The second patient--participant was a 57-year-old woman with a pathogenic *BRCA2* variant (ClinVar Variation ID 9320). Past medical history was significant for a bilateral salpingo-oophorectomy and a hysterectomy at age 42 for fibroids but was negative for cancer. EHR-documented family history ([Figure 1b](#fig1){ref-type="fig"}) was notable for a brother who died of pancreatic cancer at 37 and two relatives with colon cancer, but she did not meet referral guidelines for hereditary breast cancer risk.^[@bib10]^ Her most recent screening mammogram, at age 53, was normal. Following results disclosure, breast MRI showed a nonmass enhancement in the left breast; subsequent left diagnostic mammogram and targeted second-look ultrasound in the upper outer quadrant were normal ([Figure 2](#fig2){ref-type="fig"}; [Supplementary Figure 1c--f](#sup1){ref-type="supplementary-material"}). MRI-guided biopsy revealed ductal carcinoma *in situ* ([Supplementary Figure 1g](#sup1){ref-type="supplementary-material"}). The patient--participant underwent bilateral mastectomy and breast reconstruction. Final pathology showed ductal carcinoma *in situ* measuring 1.2 cm in its greatest dimension, grade 2 to 3, with negative sentinel lymph nodes---a stage 0 cancer associated with 20-year survival of 97%.^[@bib12]^

The third patient--participant was a 55-year-old man with a pathogenic *BRCA2* variant (ClinVar Variation ID 38082) and no personal history of cancer. EHR-documented family history ([Figure 1c](#fig1){ref-type="fig"}) did not meet genetic counseling referral guidelines.^[@bib10]^ Past medical history was significant for morbid obesity, status post Roux-en-Y gastric bypass surgery. Additionally, he had two mildly elevated PSA tests in 2007 (3.27 ng/ml---normal is less than 3.1 ng/ml) and 2008 (3.24 ng/ml) and a markedly elevated PSA test in 2015 (16.60 ng/ml). He was referred to urology after the latter elevated PSA test but did not attend an appointment. Disclosure of his *BRCA2* variant prompted his PCP to order another PSA test (eight months after the previous test), which was again markedly elevated, at 19.12 ng/ml ([Figure 2](#fig2){ref-type="fig"}). Clinical stage, based on PSA and normal digital rectal exam, was cT1c. A prostate biopsy revealed adenocarcinoma in 5/12 cores (Gleason score 4 + 4 = 8 in one core, 4 + 3 = 7 in four other cores; [Supplementary Figure 1h](#sup1){ref-type="supplementary-material"}). Computed tomography of abdomen/pelvis and bone scans were negative for metastases.

Discussion
==========

Three of 37 unselected individuals with a pathogenic *BRCA1/2* variant detected through a genomic screening program were found to have an early-stage cancer via their initial post-disclosure evaluations and risk management procedures. This is consistent with rates of occult cancer detection upon surveillance and prophylactic surgery in individuals whose *BRCA1/2* mutation was identified via family history.^[@bib13],\ [@bib14]^ These cancers were found in individuals without compelling family history documented in the EHR, adding support to the view that genomic screening programs for *BRCA1/2* variants can identify at-risk individuals who otherwise would not have come to medical attention.^[@bib2]^ By relying on genotypic detection of risk rather than on family history, the *BRCA1/2* screening approach focuses on individuals who may derive the greatest benefit from identification of risk.

Finding cancer early is not universally beneficial, as evidenced by concerns about over-diagnosis of cancer and the inability of screening modalities such as PSA testing to distinguish indolent from aggressive cancers.^[@bib15],\ [@bib16]^ Among these three cases, the benefit of early detection is clearest in the patient--participant with an early-stage diagnosis of ovarian cancer and a precursor lesion, which are difficult to screen for effectively.^[@bib17]^ Owing in part to these screening limitations, ovarian cancer is detected at a metastatic stage in 60% of cases, with associated 5-year survival of 29%.^[@bib11]^

The other two patient--participants might have benefited from genomic screening and subsequent detection of an early cancer, as well. In the patient--participant with ductal carcinoma *in situ*, the *BRCA2* result led to performing breast MRI per the evidence-based guideline^[@bib10]^---a test that was otherwise not indicated. This facilitated detection of a mammographically occult, early-stage cancer. That the ductal carcinoma *in situ* was intermediate- to high-grade is significant, as there is evidence of survival benefit from surgical treatment in such cases.^[@bib18]^ In the prostate cancer case, the patient--participant's PCP used the *BRCA1/2* variant to make a risk-based recommendation of a screening test (PSA) of controversial value to the general population.^[@bib15]^ As the patient--participant informed the Clinical Genomics team, knowledge of the *BRCA2* variant motivated him to follow up an elevated PSA result, which he had not done when prior PSA tests had been elevated. This follow-up led to diagnosis of an aggressive, Gleason 8 prostate cancer.

Our early data on performance of recommended cancer risk management---with 79% of eligible patient--participants having performed some risk management---indicate that genotypically detected variant carriers might place a similar value on risk management as their unaffected counterparts detected via family history.^[@bib19]^ The degree to which occult cancer detection and performance of recommended risk management will be replicated in other populations will be influenced by a wide variety of factors, including age, racial and ethnic diversity, and length of follow-up.

Those considering the implementation of *BRCA1/2* screening programs should note two system factors that facilitated risk management performance and cancer diagnoses and undergird the genomic screening initiative: (i) an *integrated* health-care system capable of managing cases from genome-scale testing through evaluation and risk management and (ii) a *learning* health-care system committed to studying the outcomes of clinical interventions.^[@bib20]^ A system that provides only surveillance and prophylactic surgery for individuals with genomic results cannot meaningfully contribute to evidence-based policy about the appropriateness of screening unselected individuals for genomic findings. In a learning health-care system, research and other learning activities are seamlessly integrated with standard and innovative care, all of which continuously inform one another. MyCode is a traditional genomic discovery research project, but actionable genomic results are returned to patient--participants who, supported by their clinicians, undergo traditional surveillance and prophylactic surgery. Effects on patient--participants and the health system of disclosing variants discovered via a genomic screening program (a form of innovative care) are studied (a learning activity) so that outcomes data can more readily inform clinical policies at our institution and beyond. Through this learning health-care system approach, we can learn whether returning *BRCA1/2* findings to unselected individuals offers clinical utility.
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